公开(公告)号：US20230134425A1

公开(公告)日：2023-05-04

申请号：US17929656

申请日：2022-09-02

申请人： TriAct Therapeutics, Inc.

发明人： Thomas F. WHITE

IPC分类号： A61K31/522 ,  A61P35/00 ,  C12Q1/6827 ,  C12Q1/6886

摘要： Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.

公开(公告)号：US20230123601A1

公开(公告)日：2023-04-20

申请号：US17843774

申请日：2022-06-17

申请人： Hoffmann-La Roche Inc.

发明人： Søren OTTOSEN ,  Henrik MUELLER

IPC分类号： A61K31/522 ,  A61P31/18

摘要： The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of certain antiviral compounds and immune modulator compounds.

公开(公告)号：US20230119141A1

公开(公告)日：2023-04-20

申请号：US18047742

申请日：2022-10-19

申请人： PHYTO TECH CORP.

发明人： Steven CHEN ,  Linda Shuo MAY-ZHANG

IPC分类号： A61K31/352 ,  A61K31/375 ,  A61K31/593 ,  A61K35/60 ,  A61K33/30 ,  A61K35/741 ,  A61P31/14 ,  A61K31/215 ,  A61K31/522 ,  A61K31/513 ,  A61K31/7068 ,  A61K31/675 ,  A61K31/52 ,  A61K31/7072 ,  A61K31/536 ,  A61K31/519 ,  A61K31/4706 ,  A61K39/42 ,  A61K31/4965 ,  A61K31/7052 ,  A61K31/7048 ,  A61K31/635

摘要： The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

公开(公告)号：US11602540B2

公开(公告)日：2023-03-14

申请号：US16587975

申请日：2019-09-30

申请人： BMR MEDICAL LLC

发明人： Steven Morganstern ,  Carlos Becerra

IPC分类号： A61K33/00 ,  A61K31/275 ,  A61K31/522 ,  A61K31/198 ,  A61B5/00 ,  A61H1/02 ,  A61K9/00 ,  A61K31/12

摘要： In a method of treating a patient having low blood flow that may be caused by diffused plaque and/or a plaque mass associated with Peyronie's disease in a penile region, a predetermined amount of carbon dioxide is injected into affected corpus cavernosum at a location that is adjacent to, but spaced away from the plaque mass. In addition, either before and/or after the injection of the carbon dioxide, a decalcifying agent(s) may be injected directly into the plaque mass.

公开(公告)号：US20230072225A1

公开(公告)日：2023-03-09

申请号：US17836314

申请日：2022-06-09

申请人： DUPONT NUTRITION USA, INC.

发明人： Hui S. Yang ,  Hua Ma ,  Kevin Stokes

IPC分类号： A61K9/50 ,  A61K9/28 ,  A61K31/522 ,  A61K31/554

摘要： In one aspect, the present invention is directed to a method of making a controlled release solid dosage form having an ethylcellulose coating layer, which layer comprises a coalescing agent which is an organic ester having an HLB Value of from 3 to 8. The use of such coalescing agent permits the formation of an effective controlled release coating without the need for a further curing step after the coating process. In other aspects, this invention relates to an aqueous dispersion useful in such method; as well as to the coated dosage form produced.

公开(公告)号：US20230066204A1

公开(公告)日：2023-03-02

申请号：US17784375

申请日：2020-12-18

申请人： OYE Therapeutics, Inc

发明人： Brett Dines ,  Pamela A. Smith ,  Stephen R. Byrn

IPC分类号： A61K31/522 ,  A61K47/12

摘要： The present disclosure is directed to compositions of caffeine citrate. In addition, the present disclosure includes processes of making compositions of caffeine citrate and methods of treatment using caffeine citrate. Such methods include methods of accelerating emergence from anesthesia by delivering compositions of caffeine citrate of the disclosure.

公开(公告)号：US20230057621A1

公开(公告)日：2023-02-23

申请号：US17786937

申请日：2020-10-26

申请人： XIAMEN UNIVERSITY ,  YANG SHENG TANG COMPANY, LTD.

发明人： Yixin CHEN ,  Guosong WANG ,  Pengfei HUANG ,  Ruiqi CHEN ,  Lina LIN ,  Qiangyuan HAN ,  Ningshao XIA

IPC分类号： A61K31/675 ,  A61P31/22 ,  A61K38/21 ,  A61K31/7056 ,  A61K31/522 ,  A61K31/192 ,  A61K31/616 ,  A61K31/405

摘要： The present invention relates to the medical field, and in particular to the use of adefovir dipivoxil and a structural analog thereof for treating pseudorabies virus. In particular, the invention relates to the use of a compound as shown in formula (I), a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof for inhibiting the pseudorabies virus, treating pseudorabies virus infections or treating diseases related to pseudorabies virus infections.

公开(公告)号：US11583531B2

公开(公告)日：2023-02-21

申请号：US16849349

申请日：2020-04-15

申请人： Gilead Sciences, Inc.

发明人： Sylvie M. Asselin ,  Pavel R. Badalov ,  Henry G. Morrison ,  Christopher S. Regens ,  Tiago Vieira

IPC分类号： A61K31/519 ,  A61K31/522 ,  A61K31/675 ,  A61K31/7072 ,  C07D471/04 ,  A61P31/20 ,  A61K45/06

摘要： The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.

公开(公告)号：US20230051483A1

公开(公告)日：2023-02-16

申请号：US17807057

申请日：2022-06-15

申请人： Aligos Therapeutics, Inc.

发明人： Sandrine Vendeville ,  Pierre Jean-Marie Bernard Raboisson ,  David McGowan ,  Yannick Debing

IPC分类号： A61K31/519 ,  A61K38/21 ,  A61K31/513 ,  A61K31/7072 ,  A61K31/675 ,  A61K31/522 ,  A61K31/7088 ,  C07D471/04 ,  C07D519/00 ,  A61P31/14

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230012167A1

公开(公告)日：2023-01-12

申请号：US17854801

申请日：2022-06-30

申请人： Janssen Pharmaceutica NV

发明人： Jacqueline Cirillo BUSSOLARI ,  Ulrike PHILIPPAR ,  Andrew STEELE ,  Mark S. TICHENOR

IPC分类号： A61K31/522 ,  A61K31/501 ,  A61K45/06

摘要： The present disclosure is directed to the use of a compound of Formula (III) in the treatment of DLBCL.